BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today ...

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The company has a market cap of $6.61 billion, a PE ratio of -12.20 and a beta of 1.07.

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...